CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Targeting GPRC5D for multiple myeloma therapy.
Targeting GPRC5D for multiple myeloma therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
GPRC5D 在浆细胞上几乎普遍表达，而在重要正常组织中的表达有限，因此有望成为多发性骨髓瘤（MM）的免疫治疗靶点。近年来，靶向 GPRC5D 的治疗策略受到广泛关注，包括双特异性抗体（BsAb）、嵌合抗原受体（CAR）T 细胞和抗体药物偶联物（ADC），主要用于复发/难治性 MM（R/R MM）。仍需开展更多临床试验，以确认单独使用靶向 GPRC5D 免疫疗法的长期疗效，探索其与其他特定抗原联合靶向的可能性，或研究其与现有疗法联用以克服 MM 耐药的效果。本综述概述了 GPRC5D 的当前研究进展，包括其生物学特征及从实验室研究到临床应用的转化历程。
Given its nearly ubiquitous expression on plasma cells and limited expression on essential normal tissue, the G protein-coupled receptor class C group 5 member D (GPRC5D) presents a promising opportunity for utilization as an immunotherapy target in multiple myeloma (MM). The therapeutic strategies targeting GPRC5D, such as bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T cells, and antibody-drug conjugates (ADCs), have been prominently emphasized in relapsed/refractory MM (R/R MM) in recent years.
Further clinical trials are necessary to confirm the long-term efficacy of GPRC5D-targeting immunotherapies alone, explore their potentials co-targeting with other specific antigens, or investigate their combinations with existing treatments to overcome MM resistance. This review provides an overview of current research progress in GPRC5D, encompassing its biological characteristics and translational journey from laboratory to clinical application.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
